Home Health Care Service

Top Providers in the category

PlushCare

PlushCare is a full-service virtual clinic offering FDA-approved brand-name GLP-1s only (Wegovy, Ozempic, Zepbound, Mounjaro) with board-certified doctors. Membership starts at $19.99/mo with consultations at $129 each. Best for patients who want traditional doctor visits and insurance billing.

Read More

Read Latest Articles

GLP-1 Social Stigma: What Users Face and How to Handle It

A Florida State University researcher has found that people using GLP-1 medications like semaglutide and tirzepatide often face unexpected stigma from their own social circles. This article breaks down why that stigma happens, how it affects treatment outcomes, and what you can do to protect your mental health while staying on track with your medication.

Read More

Generic Ozempic Shortage: What Patients Need to Know

Generic semaglutide (the biosimilar version of Ozempic) is running out at pharmacies across Quebec due to recalls and surging demand. If you're currently on this medication or planning to start, here's what the shortage means for your treatment and what alternatives exist.

Read More

GLP-1 Lawsuits Over Vision Loss: What Patients Need to Know

Lawsuits are emerging against GLP-1 drug manufacturers over reported cases of vision loss in some patients. This article breaks down what the legal claims involve, what the medical research currently shows, and what questions you should ask your doctor before or during treatment.

Read More

Wegovy Approved for Liver Disease in Singapore

Singapore has approved Wegovy (semaglutide) as the first medication specifically indicated for MASH with liver fibrosis, a serious liver condition affecting millions globally. This expands the growing body of evidence that GLP-1 medications do far more than help with weight loss. Here is what patients and those considering GLP-1 therapy need to know.

Read More

Medicare GLP-1 Coverage: What 700K Seniors Mean for You

Medicare's GLP-1 coverage program has reached 700,000 seniors, with Eli Lilly capturing roughly 70% of that market. This milestone signals a major shift in how older Americans access weight loss and diabetes medications, but navigating the coverage details still takes work.

Read More